Google
×
Abemaciclib is a type of cancer growth blocker that targets the proteins cyclin dependant kinase 4 and 6 (CDK4 and CDK6) on breast cancer cells. CDK 4 and CDK 6 are proteins that stimulate cancer cells to divide and grow. Abemaciclib works by blocking these proteins. It aims to slow or stop the growth of the cancer.
Apr 8, 2024
People also ask
Jun 15, 2023 ˇ Abemaciclib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply.
The recommended dose of abemaciclib is 150 mg twice daily when used in combination with endocrine therapy. Please refer to the summary of product ...
Abemaciclib is used together with tamoxifen or an aromatase inhibitor (eg, anastrozole, exemestane, letrozole) to treat hormone receptor (HR)-positive, HER-2 ...
VERZENIOŽ (abemaciclib) is indicated: • in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients ...
Abemaciclib is a medication used to treat HR+ HER2- advanced or metastatic breast cancer. Abemaciclib is an antitumor agent and dual inhibitor of cyclin- ...
Indicated as monotherapy for adults with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy ...
Aug 6, 2024 ˇ Verzenio is a pill that can be used to treat both early-stage and advanced-stage hormone receptor-positive HER2-negative breast cancer.
Abemaciclib is used to treat breast cancer that is oestrogen receptor positive (ER-positive) and HER2-negative. It can be taken by both men and women.
Abemaciclib, sold under the brand name Verzenio among others, is a medication for the treatment of advanced or metastatic breast cancers.
Visit the website to view 5 year data and helpful resources for your patients. Visit the website to find helpful resources for your patients. Resources. Adverse Reactions. Video Modules. Dosing. Efficacy and Safety. Clinical Trials. Types: Clinical Trials, Safety, Dosing, Efficacy, Savings.